• AAPL 165
  • TSLA 147.05
  • AMZN 174.63
  • MSFT 399.12
  • INTC 34.2
  • EURUSD 1.0661
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. V /
  3. ARCH.V

Arch Biopartners Inc (ARCH V) stock market data APIs

C$2 -0.38(-16%) as of April 19, 2024

Arch Biopartners Inc Financial Data Overview

2.11
2
-
2.6
2.17
0.97-2.56
150 M
62 856 K
1 847 K
0.01
1.344
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ARCH',
Type: 'Common Stock',
Name: 'Arch Biopartners Inc',
Exchange: 'V',
CurrencyCode: 'CAD',
CurrencyName: 'Canadian Dollar',
CurrencySymbol: 'C$',
CountryName: 'Canada',
CountryISO: 'CA',
OpenFigi: NULL,
ISIN: 'CA03938C1041',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'September',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Arch Biopartners Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 847 K
  • EBITDA 0
  • Earnings Per Share -0.03
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Arch Biopartners Inc Earnings via APIs

  • Latest Release 2024-02-28
  • EPS/Forecast -0.02

Get Arch Biopartners Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Arch Biopartners Inc latest news via APIs

Shares for Interest Debt Settlement

TORONTO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for de...
  • ARCH BIOPARTNERS
  • MAJOR SHAREHOLDER ANNOUNCEMENTS
  • TSX VENTURE EXCHANGE:ARCH

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministr...
  • ACUTE KIDNEY INJURY TREATMENT
  • ARCH BIOPARTNERS
  • CHRONIC KIDNEY DISEASE
  • CLINICAL STUDY
  • DOD
  • HEALTH
  • KIDNEY FOUNDATION
  • NORDISK
  • NOVARTIS
  • SAVE KIDNEYS
  • TREAT INFLAMMATION
  • TSX VENTURE EXCHANGE:ARCH
Do you have any questions?
support@eodhistoricaldata.com